ClinicalTrials.gg
RecruitingNCT06307665ACADIAUpdated Nov 10, 2026

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

A Phase 3 interventional study of BDA MDI and AS MDI in Asthma, sponsored by AstraZeneca. Recruiting at 157 sites in 4 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Nov 10, 2026Site recruiting status changed7 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Planned enrollment
81st of 248
440 · median 175
Started
2024
with 25 others
Phase 3
121 of 359
6 open now
Primary completion
2027-10
later than 13 of 27 live
Registered
316th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 81st largest by planned enrollment of the 248 interventional ones that give a count, is one of 26 that started in 2024, is one of 121 in phase 3, reaches primary completion later than 13 of the 27 other live ones, and was the 316th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.

Read the detailed description

This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.

The study will consist of 3 periods:

  1. Screening period (7 to 28 days)
  2. Treatment period of 52 weeks
  3. Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)

Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.

This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Fast-acting β2-agonist
  • Metered-Dose Inhaler (MDI)
  • Bronchodilatory
  • Inhaled corticosteroids
  • Anti-inflammatory
  • Rescue Therapy
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed clinical diagnosis of asthma at least 12 months.
  • Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month

    1. Low-to-high-dose Inhaled (s) (ICS)
    2. Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
  • Receiving inhaled short-acting β2-agonist (SABA) as needed.
  • A documented history of at least one severe asthma exacerbation within 12 months.
  • Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
  • Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
  • Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
  • Participants must adhere to protocol specific methods.
  • Negative urine pregnancy test for participants of .
  • Have a \< 40 kg/ m\^2.
  • Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
  • Experienced > 3 severe asthma exacerbations within 12 months before screening.
  • Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
  • Upper respiratory infection involving antibiotic treatment not resolved.
  • Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking \< 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
  • Other significant lung disease, including regular or occasional use of oxygen.
  • Historical or current evidence of a disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
  • Cancer not in complete remission for at least 5 years.
  • History or hospitalization for psychiatric disorder or attempted suicide within one year.
  • Significant abuse of alcohol or drugs, in the opinion of the investigator.
  • Oral (s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
  • Use of any oral SABAs within one month.
  • Having a known or suspected to albuterol/salbutamol, or budesonide and/or their .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    Budesonide/albuterol metered -dose inhaler (BDA MDI)

    Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed.

    Combination Product: BDA MDI

  • Active comparator
    Albuterol sulfate metered-dose inhaler (AS MDI)

    Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed.

    Combination Product: AS MDI

Interventions

  • Combination productPT027Studies of PT027PT027 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.

    Also known as: PT027

  • Combination productAS MDI

    Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.

    Also known as: PT007

06

What researchers measure

Primary outcomes

  1. Annualized rate of severe asthma exacerbations (AAER)

    The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated.

    Time frame: From Randomization (Day 1) to Week 52 (EOT)

Secondary outcomes

  1. Time to first (TTF) severe asthma exacerbation

    The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated.

    Time frame: From Randomization (Day 1) to Week 52 (EOT)

  2. Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma

    The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated.

    Time frame: From Randomization (Day 1) to Week 52 (EOT)

  3. Number of participants with adverse events (AEs) and severe adverse events (SAEs)

    The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed.

    Time frame: Up to Week 52

  4. Maximum Observed Concentration (Cmax)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  5. Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  6. Area under concentration-time curve from time 0 to infinity (AUCinf)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  7. Time to reach maximum concentration following drug administration (Tmax)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  8. Time of last quantifiable concentration (Tlast)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  9. Terminal elimination half-life (t½λz)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  10. Terminal elimination rate constant (λz)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  11. Apparent total body clearance (CL/F)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

  12. Apparent volume of distribution based on the terminal phase (Vz/F)

    The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized.

    Time frame: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose

07

Study locations

121 of 157 sites recruiting
  • Research Site
    Anchorage, Alaska 99508, United States
    Recruiting
  • Research Site
    Gilbert, Arizona 85234, United States
    Recruiting
  • Research Site
    Phoenix, Arizona 85016, United States
    Recruiting
  • Research Site
    Little Rock, Arkansas 72202, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Huntington Beach, California 92647, United States
    Not yet recruiting
  • Research Site
    Huntington Beach, California 92648, United States
    Not yet recruiting
  • Research Site
    Long Beach, California 90806, United States
    Recruiting
  • Research Site
    Long Beach, California 90815, United States
    Recruiting
  • Research Site
    Madera, California 93636, United States
    Not yet recruiting
  • Research Site
    Mission Viejo, California 92691, United States
    Recruiting
  • Research Site
    Moreno Valley, California 92553, United States
    Recruiting
  • Research Site
    Orange, California 92868, United States
    Recruiting
  • Research Site
    Redondo Beach, California 90277, United States
    Recruiting
  • Research Site
    Riverside, California 92506, United States
    Recruiting
  • Research Site
    San Diego, California 92123, United States
    Recruiting
  • Research Site
    San Diego, California 92123, United States
    Not yet recruiting
  • Research Site
    San Francisco, California 94143, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Westminster, California 92683, United States
    Recruiting
  • Research Site
    Denver, Colorado 80206, United States
    Recruiting
  • Research Site
    Wilmington, Delaware 19803, United States
    Recruiting
  • Research Site
    Destin, Florida 32541, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32207, United States
    Recruiting
  • Research Site
    Kendall, Florida 33176, United States
    Not yet recruiting
  • Research Site
    Largo, Florida 33777, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Miami, Florida 33142, United States
    Recruiting
  • Research Site
    Miami, Florida 33144, United States
    Recruiting
  • Research Site
    Miami, Florida 33145, United States
    Recruiting
  • Research Site
    Miami, Florida 33183, United States
    Recruiting
  • Research Site
    Miami, Florida 33185, United States
    Recruiting
  • Research Site
    Orlando, Florida 32827, United States
    Not yet recruiting
  • Research Site
    Pembroke Pines, Florida 33026, United States
    Recruiting
  • Research Site
    Tampa, Florida 33613, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Atlanta, Georgia 30329, United States
    Recruiting
  • Research Site
    Columbus, Georgia 31904, United States
    Recruiting
  • Research Site
    Fayetteville, Georgia 30214, United States
    Recruiting
  • Research Site
    Snellville, Georgia 30078, United States
    Recruiting
  • Research Site
    Meridian, Idaho 83646, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Normal, Illinois 61761, United States
    Recruiting
  • Research Site
    River Forest, Illinois 60305, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Indianapolis, Indiana 46202, United States
    Recruiting
  • Research Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Research Site
    Overland Park, Kansas 66213, United States
    Not yet recruiting
  • Research Site
    Louisville, Kentucky 40202, United States
    Recruiting
  • Research Site
    Louisville, Kentucky 40217, United States
    Recruiting
  • Research Site
    Lafayette, Louisiana 70508, United States
    Recruiting
  • Research Site
    New Orleans, Louisiana 70121, United States
    Recruiting
  • Research Site
    New Orleans, Louisiana 70125, United States
    Recruiting
  • Research Site
    Ellicott City, Maryland 21043, United States
    Recruiting
  • Research Site
    Lanham, Maryland 20706, United States
    Not yet recruiting
  • Research Site
    Silver Spring, Maryland 20902, United States
    Recruiting
  • Research Site
    White Marsh, Maryland 21162, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    Detroit, Michigan 48201, United States
    Recruiting
  • Research Site
    Mankato, Minnesota 56001, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Research Site
    Kansas City, Missouri 64108, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Kansas City, Missouri 64118, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63108, United States
    Recruiting
  • Research Site
    Missoula, Montana 59804, United States
    Recruiting
  • Research Site
    Lincoln, Nebraska 68510, United States
    Recruiting
  • Research Site
    Lincoln, Nebraska 68516, United States
    Recruiting
  • Research Site
    Omaha, Nebraska 68114, United States
    Recruiting
  • Research Site
    Newark, New Jersey 07103, United States
    Recruiting
  • Research Site
    Newark, New Jersey 07103, United States
    Not yet recruiting
  • Research Site
    Northfield, New Jersey 08225, United States
    Recruiting
  • Research Site
    Ocean City, New Jersey 07712, United States
    Recruiting
  • Research Site
    Paramus, New Jersey 07652, United States
    Recruiting
  • Research Site
    Albuquerque, New Mexico 87106, United States
    Recruiting
  • Research Site
    Albany, New York 12208, United States
    Recruiting
  • Research Site
    Cortland, New York 13045, United States
    Recruiting
  • Research Site
    Hawthorne, New York 10532, United States
    Recruiting
  • Research Site
    Hollis, New York 11423, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10019, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10032, United States
    Recruiting
  • Research Site
    New York, New York 11355, United States
    Recruiting
  • Research Site
    Rochester, New York 14607, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    The Bronx, New York 10459, United States
    Recruiting
  • Research Site
    The Bronx, New York 10461, United States
    Recruiting
  • Research Site
    Vestal, New York 13850, United States
    Recruiting
  • Research Site
    Vestal, New York 13850, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Watertown, New York 13601, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina 28277, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Durham, North Carolina 27705, United States
    Not yet recruiting
  • Research Site
    Cincinnati, Ohio 45229, United States
    Not yet recruiting
  • Research Site
    Columbus, Ohio 43205, United States
    Not yet recruiting
  • Research Site
    Columbus, Ohio 43228, United States
    Recruiting
  • Research Site
    Dayton, Ohio 45424, United States
    Recruiting
  • Research Site
    Findlay, Ohio 45840, United States
    Recruiting
  • Research Site
    Toledo, Ohio 43617, United States
    Recruiting
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
    Not yet recruiting
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
    Recruiting
  • Research Site
    Yukon, Oklahoma 73099, United States
    Recruiting
  • Research Site
    Pittsburgh, Pennsylvania 15241, United States
    Recruiting
  • Research Site
    Charleston, South Carolina 29425, United States
    Recruiting
  • Research Site
    Rock Hill, South Carolina 29730, United States
    Completed

    Not enrolling at this site — choose another above.

  • Research Site
    Sioux Falls, South Dakota 57105, United States
    Recruiting
  • Research Site
    Nashville, Tennessee 37232, United States
    Recruiting
  • Research Site
    Austin, Texas 78759, United States
    Recruiting
  • Research Site
    Baytown, Texas 77521, United States
    Recruiting
  • Research Site
    Beaumont, Texas 77701, United States
    Recruiting

Showing the first 100 of 157 sites across 4 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bacharier LB, Raissy H, Bardsley S, Dunsire L, Hermansson E, Surujbally R, Sobande O, Murphy KR. Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial. BMJ Open Respir Res. 2026 Mar 6;13(1):e003843. doi: 10.1136/bmjresp-2025-003843. PubMed 41791845 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2027, 40 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 40 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 13, 2024
StartActual
May 20, 2024
Primary completionEst.
Oct 13, 2027
CompletionEst.
Oct 13, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added. 11 sites changed recruiting status (10 now recruiting, 1 now not yet recruiting)
Show 11 sites
  • Research Site · Miami, United StatesNot yet recruiting→Recruiting
  • Research Site · Pembroke Pines, United StatesNot yet recruiting→Recruiting
  • Research Site · Louisville, United StatesNot yet recruiting→Recruiting
  • Research Site · St Louis, United StatesNot yet recruiting→Recruiting
  • Research Site · El Paso, United StatesNot yet recruiting→Recruiting
  • Research Site · Oklahoma City, United StatesRecruiting→Not yet recruiting
  • Research Site · Corpus Christi, United StatesNot yet recruiting→Recruiting
  • Research Site · Redondo Beach, United StatesNot yet recruiting→Recruiting
  • Research Site · New York, United StatesNot yet recruiting→Recruiting
  • Research Site · Beaumont, United StatesNot yet recruiting→Recruiting
  • Research Site · Dallas, United StatesNot yet recruiting→Recruiting
Show 7 added (7 United States)
  • Research Site · Miami, United States
  • Research Site · Orlando, United States
  • Research Site · Corpus Christi, United States
  • Research Site · Dallas, United States
  • Research Site · Oklahoma City, United States
  • Research Site · Overland Park, United States
  • Research Site · Newark, United States
across 3 updates, Oct 9, 2026 – Nov 10, 2026
Show all 3 updates
  1. Nov 10, 2026
    2 sites added. 5 sites changed recruiting status (5 now recruiting)
    Show 5 sites
    • Research Site · Redondo Beach, United StatesNot yet recruiting→Recruiting
    • Research Site · Miami, United StatesNot yet recruiting→Recruiting
    • Research Site · New York, United StatesNot yet recruiting→Recruiting
    • Research Site · Beaumont, United StatesNot yet recruiting→Recruiting
    • Research Site · Dallas, United StatesNot yet recruiting→Recruiting
    Show 2 added (2 United States)
    • Research Site · Overland Park, United States
    • Research Site · Newark, United States
    + 1 other change: verification date
  2. Oct 13, 2026
    1 site added. 2 sites changed recruiting status (1 now not yet recruiting, 1 now recruiting)
    Show 2 sites
    • Research Site · Oklahoma City, United StatesRecruiting→Not yet recruiting
    • Research Site · Corpus Christi, United StatesNot yet recruiting→Recruiting
    Show site
    • Research Site · Oklahoma City, United States
  3. Oct 9, 2026
    4 sites added. 7 sites changed recruiting status (6 now recruiting, 1 now not yet recruiting)
    Show 7 sites
    • Research Site · Miami, United StatesNot yet recruiting→Recruiting
    • Research Site · Miami, United StatesNot yet recruiting→Recruiting
    • Research Site · Miami, United StatesRecruiting→Not yet recruiting
    • Research Site · Pembroke Pines, United StatesNot yet recruiting→Recruiting
    • Research Site · Louisville, United StatesNot yet recruiting→Recruiting
    • Research Site · St Louis, United StatesNot yet recruiting→Recruiting
    • Research Site · El Paso, United StatesNot yet recruiting→Recruiting
    Show 4 added (4 United States)
    • Research Site · Miami, United States
    • Research Site · Orlando, United States
    • Research Site · Corpus Christi, United States
    • Research Site · Dallas, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06307665
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
May 20, 2024
Primary completion
Oct 13, 2027 (estimated)
Completion
Oct 13, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PT027

Start the discussion